Download Teaching Philosophy - Center for Excellence in Teaching and

Teaching Portfolio
C. Michael White, Pharm.D., FCP, FCCP
Professor and Head
Department of Pharmacy Practice
University of Connecticut
02/02/12
Table of Contents:
1. Teaching Responsibilities
2. Teaching Philosophy and Approach
3. Teaching Goals and Awards
4. Formal Letters of Teaching Assessment
5. Student Didactic Teaching Assessment
6. Student Experiential Teaching Assessment
7. Non-Research Symposia/CE Programs
8. Research Evaluating my Teaching
10. Book Chapters and Review Articles of Note
Section
A
B
C
D
E
F
G
H
I
Teaching Responsibilities
Section A
C. Michael White, Pharm.D., FCP, FCCP
Professor of Pharmacy
University of Connecticut
TEACHING
EXPERIENCE
Student/Resident
Precepting
Jan 1996 – Precepted Undergraduate (UConn, Albany College of Pharmacy) and PharmD students
Present (UConn, SUNY Buffalo, Creighton, Ohio Northern, Mass College of Pharmacy) (n>300).
July 1998 – Precepted Pharmacy Practice Residents (Hartford Hospital, Connecticut VAMC) (n=18).
Present
Graduate Fellows
August 1998 – July
1999
July 2002-June
2003
August 1998 –
June 2006
June 2006 –
Present
Interim Director of the Outcomes Research Fellowship at Hartford Hospital
Graduated Fellow: Prabashni Reddy, Pharm.D.
Interim Director of the Outcomes Research Fellowship at Hartford Hospital
Graduated Fellow: Craig Coleman, Pharm.D.
Director of the Cardiovascular Outcomes Fellowship at Hartford Hospital
Graduated Fellows:
Alisha Dunn, Pharm.D. June 1999, Medical Science Liason Manager, Scios
Pharmaceuticals
James Tsikouris Pharm.D. June 2000, Currently Assoc Prof, University of
Pittsburgh
Jessica Song, Pharm.D. June 2001, Currently Assoc Prof, Univ of the Pacific
Michael Caron, Pharm.D. June 2002, Currently Medical Science Liason, Canyon
Pharmaceuticals
James Kalus, Pharm.D. June 2003, Currently Assoc Director, Henry Ford Hospital
Brian McBride Pharm.D., June 2004, Currently Asst Prof, Loyola University
Bokyung Min, Pharm.D. July 2005, Currently Asst Prof, Nova Southeastern.
Stephen Sander, Pharm.D. March 2006, Currently Manager, Outcomes Researcher,
Boringer-Ingelheim Pharmaceuticals,
Nickole Henyan, Pharm.D. June 2006, Currently Clinical Specialist, Shore Health
System
Krista Dale, Pharm.D. June 2007, Currently Clin Spec, Mississippi Medical Center
Sachin Shah, Pharm.D. June 2007, Currently Asst Prof, Univ of the Pacific
William L Baker, Pharm.D., BCPS., Currently Asst Prof, UCONN
Kurt Reinhart, Pharm.D., Currently Asst Prof. Wingate University.
Ripple Talati, Pharm.D., Senior Scientist, UCONN/HH EPC
Olivia Phung, Pharm.D., Currently Asst Prof, Western University
Co-Director of the Cardiac Outcomes Fellowship at Hartford Hospital
Current Fellows: Jennifer Colby, Pharm.D., Wendy Chen, Pharm.D.,
Jennifer Scholle, Pharm.D., Soyon Lee, Pharm.D.
Visiting
Scholars/Pharm.D.
Students
Feb 1999 - Sept
1999
Feb 2002 – Apr 2003
Apr 2008
Apr 2010
Jul 2010
Student Research
1999-Present
Preceptor of Two Visiting Scholars (MDs) in Cardiovascular Pharmacology, Hartford, CT
Graduated Scholars: Jianlin Xie, MD, Yianling Sun, MD (September 1999)
Preceptor of Visiting Scholar (Pharmacist) in Cardiovascular Pharmacology, Hartford, CT
Graduated Scholar: Liu Xing, MS Pharmacy.
Preceptor of Two French Students from the University de Rennes, Hartford, CT
French Students: Anais Le Rhun, Elodie E Raider
Preceptor of Two French Students from the University of Rennes, Hartford, CT
French Students: Anne-AmélieCuris, Nadege Seznec.
Preceptor of Student from University of Puerto Rico, Hartford, CT
Student: Nahir Rivera
Preceptor of Undergraduate Research Students, UConn School of Pharmacy, Storrs, CT
Graduated with Honors: Rabab Ammar, Pharm.D. (2 Semesters, May 2001).
Agnes Krudysz Pharm.D. & Angie Karapanos Pharm.D. (2 Semesters + 1 Rotation Month, May
2004). Pauline Rafferty (May 2005)
Graduated with Distinction: Audrea Hotsko Pharm.D. & Stacey Robertson, Pharm.D. (2 Semesters +
1 Research Month, May 2002), Alexandria Piotrowski, Pharm.D. (2 Semesters + 1 Research Month,
May 2003), Deborah Cios, (4 Semesters, September 2004-May 2007)
Graduated Students: Jenny Chung, Pharm.D. (February 2002), William Baker, Pharm.D. (March
2002), Audrea Hotsko, Pharm.D. and Steven Sander, Pharm.D. (April 2002), Heather Sun, Pharm.D.
and Nick Hawryz, Pharm.D. (April 2003), Christopher Fortier, Pharm.D., Vinnita Sinha, Pharm.D.
(April 2004), Michael Kardas, Pharm.D.& Agron Ismaili, Pharm.D. (2 Semesters Ending + 1 rotation
ending June 2004), Jade Pham, Pharm.D. (July 2004), Jasmine Sahni, Pharm.D. (January 2005), Sean
Norton (July 2005), Elizabeth Lucina (April 2006), Aaron Hussey (June 2006), Jennifer Morrone
(August 2006), Eang Lao (October 2006), Jenny Lipieki (3 semesters January 2005-May 2007),
Payal Vachhani (Two semesters, 2007-2008, HONORS), Colleen J Teevan (January 2007-2010,
HONORS), Lauren Tuttle (Two Semesters, 2008-2010 HONORS)
Current Research Students: Agata Dabek (P3), Katarzyna Zlotnik (P3),
Preceptor of Research Training Experience, St Joseph’s College, Hartford, CT
Graduated Student: Lilia Mandybur (2 Semesters Ending August/December 2001)
UConn Didactic
Courses
Undergraduate
1997-1998 Pharmacokinetics (Pharmacy 230). Lecturer on Antiarrhythmic Drug
Pharmacokinetics
1998-1999 Cardiovascular Therapeutics Module (Pharmacy 280). Lectures on
Angina/Myocardial Infarction, Hypertension, Thromboembolism, Arrhythmias,
Congestive Heart Failure
1998-1999 Pharmacy Research Seminar (Pharmacy 201) for Honors Program Students.
Lecturer on Research
Pharm.D. Program
1998-Present Pharmaceutical Care (PHRM 207). On-Site Lecturer
1998-Present Cardiology Therapeutics Module (PHRM 254). Lectures on Hyperlipidemia,
Angina, Myocardial Infarction, Arrhythmias, Congestive Heart Failure
2003-Present Cardiology Therapeutics Module (PHRM 254). Lecture on Cardiovascular Drugs
Pharmacokinetics
2005-2006 Cardiology Therapeutics Module (Phrm 254): Lecture on Hypertension and
Interpreting Acid-Base Disorders.
1999-2009 Literature Evaluation and Biostatistics (PHRM 200/PHRX 3000). Course CoCoordinator and Lecturer.
1999-2002 Clinical Pharmacokinetics (PHRM 257). Lecturer on Antiarrhythmic Agents
Pharmacokinetics
1999-2000 Pharmacy Research Seminar (PHRM 201) for Honors Program Students. Lecturer
on Research
1999-2005 Physical Assessment Course (PHRM 211). Lecturer (ECG Skills/Heart Sounds),
Laboratory Instructor (CV exam plus GI exam).
2001-2003 Nonprescription Medication Course (PHRM 210). Lecture on Head & Body Lice.
2003 – Present Nonprescription Medication Course (PHRM 210). Lecture on Herbs With Cardiac
Implications.
2006 – 2007 Drug Induced Diseases (PHRM 258W). Lecture on Drug Induced Cardiac Disease
and Preceptor of Major Student Writing Projects
2008 – 2009 Pharmacy Honors Seminar (Phar 201). Lecture on Research Aimed to Prevent Drug
or Surgery Induced Diseases.
2008 – Present Evidence-Based Practice (PHRX 3095, ELECTIVE). Lectures on Evidence Based
Practice and Use of Systematic Review to Discern that Evidence.
2009-2010 Pharmacy Honors Seminar (Phar 201). Lecture on Research Related to Eviencebased Practice.
2009 – Present Drug Information II (PHRX3007). Lectures on Interpreting Primary Literature and
Statistical Analysis.
Masters in Clinical
Translational
Research
2008-2010 Core III: Evidence Based Practice. Lectures on Evidence-Based Practice and Use of
Meta-Analaysis/Systematic Review to Discern Evidence. UCHC, Farmington, CT.
Hartford Hospital
Didactic Courses
1996-2002 Advanced Practice Registered Nurse Certification Program (APRN). Lecturer on
Cardiovascular Therapeutics
1996-2003 Advanced Cardiac Life Support Certification Program (ACLS). Pharmacology
Lecturer.*
* - Awarded Best ACLS Teaching Program in New England 1999.
Hartford
Hospital Department of Pharmacy Core Competencies Lecture Series. Lectures on
2001-Present
Myocardial Infarction, Congestive Heart Failure, Hyperlipidemia, and Arrhythmias
Completed Annually and Video Taped. Video Tapes are Mandatory for New Pharmacist
Orientation Period.
2001-2009 University of Connecticut School of Medicine Medical Intern and Resident Pharmacology
Lectures at Hartford Hospital. Lectures on Myocardial Infarction, Congestive Heart Failure,
Hyperlipidemia, and Arrhythmias Completed Annually.
2002-2009 Hartford Hospital Division of Cardiology Fellow Lecture Series. Annual Lectures on
Research Within our Group and Treatment of Hypertension.
2003-2007 Coordinator of Advanced Cardiac Life Support Certification Pharmacology Lectures.
Teaching Philosophy and Approach
Section B
C. Michael White, Pharm.D., FCP, FCCP
Professor of Pharmacy
University of Connecticut
“Some people talk in their sleep. Lecturers talk while other people sleep.”
– Albert Camus
The pharmacy profession entrusts me to train competent and compassionate future
pharmacists and to continue the training of current pharmacists. Pharmacists of
yesteryear such as Albert White and Henry Palmer have demonstrated to me through
their actions what an awesome responsibility that is. Their love and dedication for their
profession was passed down to me and I have a responsibility to pharmacists of the past
like them and to the pharmacists of tomorrow to bestow drug knowledge while also
instilling a sense of pride in the profession and a real personal concern for patient care.
As such, I believe that I need to be a teacher, facilitator, and leader. The important tenets
of didactic and experiential teaching to which I ascribe are delineated below.
As you read the tenets of my pedagogical approach, I hope you will appreciate that I did
not just stumble upon this philosophy and approach. I started with a strong baseline
teaching approach (emulated from the professors that impacted me such as Ronald Gailey
and Robert Hamilton) and then continued to refine it over the years. Discussions with
other instructors, reading books on leadership and teaching, and through self assessment I
have identified some weaknesses and attempted to correct them by trying some new
things. However, the biggest changes in my teaching have arisen from discussion that I
have had with the students about what instructors they love, what they love about them,
what are the things that I do well, and what I could do to improve my pedagogy. This
open exchange of ideas has been the primary driver of teaching improvement. Based on
this feedback and self-assessment I developed Pharmacist Interactive Clinical Cases
(PICCs). This learning platform seems especially well suited to demonstrating the use of
drug knowledge in the simulated care of the patient. With this case approach, I have first
used study methodology to evaluate instructional effectiveness. Overall, the PICCs cases
rated much higher amongst pharmacy students than standard case based teaching formats.
Didactic Teaching: I believe that there are 5 qualities that a teacher needs to have to
underpin optimal didactic pedagogy. I have tried to incorporate these in my teaching
wherever possible.
1. Pragmatic: To use the time allocated in a manner that optimizes the learning
experience. By starting with the time allocated to a certain topic and then
devising a the lecture content, I can determine the most important topics to be
covered and allow time to enrich the content with examples and cases,
empowering the students to learn and to utilize the information in their
professional lives, and to prevent boredom that sucks out student’s life force over
the course of the class period. I think that teachers get into trouble when they are
given a topic and think that it is a mandate that they need to cover 5 hours of
material in 3 hours. This stifles creativity, creates frustration amongst students,
and prevents optimal student learning.
2. Enriching: To provide not only the content but to provide context. Context is
important because it helps students see how the knowledge can be learned,
understood, and used in their professional lives. A Chinese Proverb states a
learning philosophy: “Tell me and I will forget, show me and I may remember,
involve me and I will understand.”
3. Empowering: Even if students understand a concept and know how it can be used
in patient care, that doesn’t assure that they will use that information in that
manner in their professional lives. Students, like most everyone, need to be
inspired to act for the betterment of their patients. To create a caring health
professional, real life examples of medical care gone wrong due to a lack of
involvement and the impact of a health professional on a patient’s life really does
motivate students in a positive way.
4. Not Boring: The best content and the snappiest slides will not achieve optimal
knowledge attainment if the students are bored. The use of enrichment to help
understanding and involvement of the students in the learning process as well as
empowering students are important techniques to stave off boredom. However,
the use of humor dispersed sparingly throughout the class period that is loosely or
integrally related to the topic material not only stimulates interest but also makes
the faculty person seem more approachable and human. If done too much, it can
causes a loss of student focus and distracts from learning.
5. In Control: While some measure of lightheartedness in class is valuable and
student perception that it is ok to ask questions is valuable, the majority of
students should not be disadvantaged from learning due to disruptive students.
Acceptable student conduct needs to be explicitly spelled out and the faculty
member needs to assure that a single student does not have the capacity to derail
the learning of the majority. I am sure that at this point most people reading this
are thinking about the poorer quality student or the class clown and do occur.
However, advanced or truly gifted students can also derail learning by incessantly
asking questions that while delivered at a high level and are not relevant to vast
majority of students. In both circumstances, the faculty person needs to
communicate with the student out of class and explain what the concern is and
how to remedy it. For example, the advanced students should know that you
would be happy to answer these questions out of class and would enjoy the
discussion but the problem associated with having a two person conversation in
front of a class of 100 students given dense learning content.
Experiential Teaching: Similarly, I believe that an optimal experiential rotation is
underpinned by 4 main qualities. I try to incorporate these qualities into my experiential
rotations every month.
1. Assuring: Students need to achieve a standard level of clinical knowledge before
initiating patient contact. I believe that students should be intensively trained and
their knowledge assessed for the first 2 days of the rotation before they are
allowed to start interacting with other health professionals. A third day can be
added if needed. If students do not have adequate baseline knowledge, they have
nothing to contribute to the healthcare team initially. This means that they run the
risk of being made an outsider for the entire month even when they catch on and
have something to contribute. By assuring the healthcare team that only well
trained students are on rounds, members of the healthcare team are more likely to
incorporate students into the team earlier and more fully so students can have the
optimal experience.
2. Empowering: Making students go into the patient’s room and introduce
themselves and let the patient and their family know they will be looking at the
patient’s drugs to prevent drug interaction, assure optimal dosing, and to help in
drug selection is a wonderful technique to help students accept ownership for the
patient’s health. In afternoon discussions, reinforcing that the patients they are
presenting are real people and that they are in need of good pharmaceutical care to
help the student accept personal responsibility for the patient. If a student can see
the patient as a person rather than a case or a project than you do not have to
motivate them, just guide them.
3. Facilitative: Students need to be able to practice their craft. If their rotation
preceptor is with them all the time and is taking the lead, the student does not get
to feel the responsibility for direct patient care. They know that their responses
will be filtered through another person which waters down their experience. By
having students meet intensively early on to assess knowledge competency,
shadowing the students on rounds for the first 5 rounding days (more if needed),
and then giving them the freedom to round on their own for the rest of the rotation
seems to be a good approach. By meeting daily to discuss all patients before the
end of the day, students can discuss their patients and try out their potential
interventions to see if they should be made before going on rounds. I call this
process facilitative independence.
4. Intense to the End: The end of a rotation can create a lull in learning and growth.
The students can extract chart information with greater ease, they know what is
expected with patient presentations during preceptor discussions, and they see the
end of the rotation coming. Over the course of the month, students have been
exposed to new drugs, new knowledge about these drugs, and new approaches to
treating patients but there needs to be an impetus for students to take this
knowledge and incorporate it into their long term memory. Only then can the
knowledge be applied to future patients. Incorporating an end of rotation oral
final exam that focused on the drug knowledge that should have been attained
helps meet the aforementioned goals. Having students deliver a high quality
formal presentation to the faculty on site, residents, and fellows also help students
develop confidence in their ability to teach and enhances their drug knowledge.
By scheduling the presentations towards the end of the rotation, students have an
activity to work at that can also help prevent the end of rotation lull.
Teaching Goals and Awards
Section C
C. Michael White, Pharm.D., FCP, FCCP
Professor of Pharmacy
University of Connecticut
Short Term Goals:
1. Revise lectures for my current courses to continue to provide updated and
clinically relevant lecture material.
2. Enhance Pharmacist Interactive Clinical Cases (PICCs) to encompass more
physical assessment.
3. Design 1 additional PICC for additional educational content.
Long Term Goal:
1. Advance the use of active learning and integration of knowledge across modules
through an additional focus on PICCs in my portion of the new curriculum.
2. Maintain a highly effective advanced pharmacy practice experience rotation in the
face of mounting demands on my time as department head.
Teaching Awards:
March 2001 Teacher of the Year, University of Connecticut School of Pharmacy, Storrs, CT.
March 2004 Teacher of the Year, University of Connecticut School of Pharmacy, Storrs, CT.
April 2006 Teaching Fellow Designation Awarded. University of Connecticut. Highest University
Teaching Award. Storrs, CT.
June 19, 2006 Hartford Courant: Featured in Article Entitled “Professor’s Comic Touches Help Students
Learn” for a Statewide Newspaper. Hartford, CT
The School of Pharmacy graduating class nominates the Teacher of the Year while
the University of Teaching and Learning at the University of Connecticut Designate
Teaching Fellows.
Formal Letters of Teaching Assessment
Section D
C. Michael White, Pharm.D., FCP, FCCP
Professor of Pharmacy
University of Connecticut
Faculty Letters Include:
1. Alex Cardoni Formal Teaching Evaluation, March 2000
2. Rafaat Seifeldin, Pharm.D., PhD Teaching Fellow Award Nomination Letter,
February 2005.
3. Robert McCarthy, PhD, Teaching Fellow Award Nomination Letter, February
2005.
4. Robert McCarthy, PhD, Teaching Fellow Award Nomination Letter, February
2006.
5. Craig Coleman, Pharm.D., Teaching Fellow Award Nomination Letter, February
2005.
6. Jennifer Ellis, Pharm.D., Teaching Fellow Award Nomination Letter, February
2005.
7. Marla Campbell, Pharm.D., Teaching Fellow Award Nomination Letter, February
2005.
8. Philip Hritcko, Pharm.D., Teaching Fellow Award Nomination Letter, February
2006.
9. Michael Gerald, PhD, Teaching Fellow Award Nomination Letter, February
2006.
10. Michael Gerald, PhD, Evaluation Letter on my Lecture in “Careers in Pharmacy”
Course. January 2005.
11. American College of Clinical Pharmacy Review of Research Fellowship Training
Program. July 2001.
Student Letters Include:
1. Michael Kardas, Teaching Fellow Award Nomination Letter, February 2005.
2. Pauline Rafferty. Teaching Fellow Award Nomination Letter, February 2005.
3. Iwona Zalewska. Teaching Fellow Award Nomination Letter, February 2005.
4. Debarah Cios and Jennifer Lipeika. Teaching Fellow Award Nomination Letter,
February 2006.
5. Wanchen Tsao. Teaching Fellow Award Nomination Letter, February 2006.
6. Agron Ismaili. Teaching Fellow Award Nomination Letter, February 2005
7. Misc Cards from Past Students.
Student Evaluations of Teaching
Section E
C. Michael White, Pharm.D., FCP, FCCP
Professor of Pharmacy
University of Connecticut
02.07.11
Student Evaluations of Teaching are given for every course where a faculty member
teaches more than 6 hours of content and are on a 10 point scale with higher scores
associated with better perception of teaching. For every course evaluated, my Student
Evaluation of Teaching Scores were above the departmental average, except one. In the
one instance where my SET score was at the average (Spring 2009), this was the only
time my name was hand written on the SET form, not mechanically imprinted. I am not
sure if the form was ascribed to me in error. My average score over all years is
9.300.45 versus the departmental average of 8.310.43, p<0.0001.
Year
1998 Fall
1999 Fall
2001 Spring
2001 Fall
2002 Fall
2003 Fall
2004 Spring
2004 Fall
2005 Spring
2005 Fall
2006 Spring
2006 Fall
2007 Spring
2007 Fall
Spring 2008
2008 Fall
2008 Fall
2009 Spring
2009 Spring
2009 Fall
2010 Spring
2010 Fall
2010 Fall
2011 Spring
Fall 2011
Fall 2011
Spring 2012
Dr White
Dept Avg
SET Scores Scores
9.6
9.7
8.9
8.5
9.3
9.2
9.4
9.4
9.5
9.6
9.2
9.6
9.2
9.5
9.6
9.5
9.2
9.6
7.8
9.4
8.7
9.6
9.8
8.9
9.9
9.3
8.5
7.1
7.8
7.9
8.1
7.9
8.3
8
8.2
8
8.3
8.3
8.4
8.7
8.3
8.5
8.4
9
8.7
7.8
8.9
8.2
8.7
8.9
8.2
8.9
8.6
8.4
Course Type
Therapeutics
Drug Lit Eval
Therapeutics
Drug Lit Eval
Drug Lit Eval
Drug Lit Eval
Therapeutics
Drug Lit Eval
Therapeutics
Drug Lit Eval
Therapeutics
Drug Lit Eval
Therapeutics
Drug Lit Eval
Therapeutics
Drug Lit Eval
Evidence Based Practice
Therapeutics
Drug Info II
Drug Lit Eval
Evidence-based Practice
Cardiac Module
Evidence-based Practice
Drug Info II
Evidence-based Practice
Cardiac Module
Drug Info II
Student Evaluations of Precepting
Section F
C. Michael White, Pharm.D., FCP, FCCP
Professor of Pharmacy
University of Connecticut
Student Evaluations of Precepting (SEP) scores are the average score on a scale of 0-5
points from students on experiential rotations (Advanced Practice Pharmacy
Experiences). Of the 16 years where I had SEP scores, my SEP scores fell below the
departmental average in two of the years (2006 and 2007). At that time I became the
Director of the UCONN/Hartford Hospital EPC and increased scholarly time to 70-80%
(from 40% previously) with no reduction in the number of students I took. I needed to
dramatically reduce the time I spent with rotational students and utilize my research
fellows in a more substantive way, which took a few months (spanning two academic
years) to figure out. I am very pleased that since that time, I have created the right
experience and am again providing an above average experience. Since 2006 I am only
doing half of the normal rotational teaching and half the credit goes to the fellows that coprecept these experiences.
1996
1997
1998
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
Dr White SEP
Scores
4.87
4.93
4.75
4.56
4.93
4.73
4.92
4.6
4.84
4.36
4.06
4.9
4.75
4.8
4.85
4.87
Dept Avg
Scores
4.3
4.5
4.4
4.5
4.3
4.2
4.4
4.45
4.72
4.58
4.62
4.7
4.7
4.58
4.56
4.74
Non-Research Symposia/CE Programs
Section G
C. Michael White, Pharm.D., FCP, FCCP
Professor of Pharmacy
University of Connecticut
To date, I have delivered over 250 non-research lectures to Physicians, Pharmacists, and
Nurses. I have given medical and cardiology grand rounds and at both American Society
of Health System Pharmacists and American College of Clinical Pharmacy meetings. A
listing of the most important presentations I have delivered are summarized below.
Evaluations of these presentations have been exemplary but only a sample of these
evaluations are included.
NON-RESEARCH
PRESENTATION
Oct 10, 1995
Sept 30, 1996
Selected From Over 250 Sponsored Lectures:
Drug Induced Respiratory Diseases: Focus on Apnea and
Bronchoconstriction.
Pharmacy Practice Institute: CE Program: Pharmacists: Albany, NY
Adverse Drug Reactions and Drug Interactions of Cardiovascular
Drugs
Continuing Professional Education Service: CE Program: Pharmacists:
Wethersfield, CT
July 24, 1997
Recent Advances in Heart Failure
Connecticut Pharmacists Association: CE Program: Pharmacists: Rocky Hill, CT
Nov 15, 1997
Apr 4, 1998
Apr 7, 1998
Jul 15, 1998
Aug 18, 1998
Jan 25, 1999
Understanding the Pathophysiology and Pharmacotherapy of
Depression
Continuing Professional Education Service: CE Program: Pharmacists:
Wethersfield, CT
A Review of the Pharmacologic, Pharmacokinetic, and Therapeutic
Differences of HMG CoA Reductase Inhibitors.
Cardiology Noon Conference: St. Francis Hospital. Cardiologists, Medical
Residents: Hartford, CT
The Role of Catecholamines and Their Blockade in Heart Failure
Connecticut Managed Care Consortium: Managed Care Pharmacists, Disease Case
Managers: Rocky Hill, CT
A Comprehensive Review of HMG CoA Reductase Inhibitors for Community
Pharmacists.
Western Massachusetts Pharmacy Conference: CE Program: Community
Pharmacists: West Springfield, MA
HMG CoA Reductase Inhibitors: An Evolving class.
CE Program: Clinical Pharmacists, Managed Care Pharmacists, Avon, CT
The Extrahepatic Pharmacological Effects of HMG CoA Reductase
Inhibitors
Medical Grand Rounds, Berkshire Medical Center, Berkshire, MA
June 10, 1999
The Pharmacologic and Pharmacokinetic Effects of HMG CoA
Reductase Inhibitors
New York State Pharmacist’s Association. CE Program: Poughkeepsie, NY
June 28, 1999
Cytochrome P450 Drug Interactions with HMG CoA Reductase
Inhibitors
Albany Veterans Administration Medical Center: Albany, NY
Sept 9, 1999
Dec 4, 1999
Jan 20, 2000
Mar 10, 2000
Mar 10, 2000
Mar 16, 2000
Mar 21, 2000
May 25, 2000
May 28, 2000
Jun 24, 2000
Aug 25, 2000
Sept 19, 2000
Oct 25, 2000
Oct 27, 2000
January 5, 2001
January 18, 2001
April 10, 2001
April 17, 2001
An Update on the Therapeutic Management of Heart Failure Patients
Kentucky Society of Health-System Pharmacists: CE Program: Lexington, KY
Pharmacologic and Pharmacokinetic Comparison of ACE Inhibitors PostMyocardial Infarction
ASHP Midyear Meeting: Consensus Conference: Orlando, FL
A Review of CYP 3A4 Drug Interactions for the Pharmacist.
Mid-Hudson New York State Pharmacy Council: CE Program: Newburgh, NY
ACEIs in the Treatment of CHF/Post-MI Sequelae.
California Society of Health-System Pharmacists: CE Program: Oakland, CA
ACEIs: A Rationale for Formulary Decisions.
California Society of Health-System Pharmacists: CE Program: Oakland CA
Evaluating the Drug Literature: Tips for Primary Care Professionals
Continuing Education Grand Rounds: The Institute of Living: Hartford, CT
A Review of the Pharmacologic and Pharmacokinetic Differences of HMG
CoA Reductase Inhibitors
Connecticut Society of Health-System Pharmacists March Meeting: CE program:
Farmington, CT
A Review of the Pharmacologic Differences of HMG CoA Reductase
Inhibitors
Greater Bridgeport Pharmacy Council Meeting: CE Program: Bridgeport, CT
The Use of Intravenous Amiodarone in the Cardiac Arrest Patient.
Wyndham Hospital Quarterly Emergency Department Meeting: EMTs, ED
Physicians and Nurses: Wyndham, CT
Drug Interactions Between Cardiovascular Drugs and Over the Counter or
Herbal Products.
Connecticut/Mid-Hudson NY VNA Annual Meeting: CE Program: Newtown, CT
Review and Comparison of Thrombolytic Agents.
Eastern Conference Health Network Pharmacists, Nurses, ED Physicians:
Manchester Memorial Hospital: Manchester, CT.
A Pharmacokinetic and Safety Comparison of HMG CoA RIs.
CE Program: Pharmacists: Norwalk, CT.
A Pharmacokinetic and Safety Comparison of HMG CoA RIs.
CE Program: Physicians: Rye Brook, NY.
A Review of Thrombolysis in Acute Myocardial Infarction for Hospital
Pharmacists.
CE Program: Pharmacists: CSHP Catch the Wave Meeting: Meridan, CT
An Update on Research in the Arrhythmia and Cardiovascular Pharmacology
Group.
Cardiology Noon Conference: Cardiologists: Hartford Hospital, Hartford, CT
A Review of Pregnancy Drug Guidelines and Pregnancy Categories.
Internal Medicine Morning Conference: Internists: Hartford Hospital, Hartford, CT
An Update on the Pharmacotherapy of Acute Myocardial Infarction.
CE Program: Pharmacists, Hartford Hospital, Hartford, CT
An Update on the Pharmacotherapy of Congestive Heart Failure.
CE Program: Pharmacists, Hartford Hospital, Hartford, CT
April 24, 2001
December 3, 2001
December 3, 2001
December 4, 2001
December 11, 2001
January 18, 2002
February 14, 2002
March 21, 2002
Moderator: Therapeutic Debates on (1) Implantable Defibrillators Versus
Antiarrhythmics and (2) Use of Abciximab as First Line Therapy in PCI.
CE Program: American College of Clinical Pharmacists Meeting. Salt Lake City,
Utah
Moderator: A Review of Critical Differences Between Drugs Within Common
Cardiovascular Drug Classes.
CE Program: Midyear Clinical Meeting of the American Society of HealthSystems Pharmacists. New Orleans, LA
A Review of Critical Differences Between HMG CoA RIs.
CE Program: Midyear Clinical Meeting of the American Society of HealthSystems Pharmacists. New Orleans, LA
QTc Prolongation, How Much is Too Much?
CE Program: Part of the Cardiovascular Implications of Atypical Antipsychotics.
American Society of Health-Systems Pharmacists Dinner Program. New Orleans,
LA
Intravenous Amiodarone in Sustained Ventricular Tachyarrhythmias.
CE Program: Registered Nurses, APRNs: Education Resource Center, Hartford,
CT.
QTc Prolongation: How Much is Too Much?
Psychopharmacology Grand Rounds, CE Program: Psychiatrists, Psychiatric
Pharmacists, Nurses: Institute of Living, Hartford, CT.
An Update on New Pharmacologic Agents for Advanced Cardiac Life
Support
Physicians, Registered Nurses: Franklin Square Hospital, Baltimore, MD.
An Update on New Pharmacologic Agents for Advanced Cardiac Life
Support
Pharmacists, Registered Nurses: Physicians Community Hospital, Lanham, MD.
March 27, 2002
QTc Prolongation: How Much is Too Much?
April 25, 2002
Pharmacists, Nurses, Psychiatrists, Capital Region Mental Heath Facility.
Hartford, CT.
An Update on New Pharmacologic Agents for Advanced Cardiac Life
Support
Registered Nurses, Physicians, Hartford, CT
May 2, 2002
QTc Prolongation: How Much is Too Much?
Physicians. Department of Psychiatry. Baystate Medical Center. Springfield, MA.
May 14, 2002
QTc Prolongation: How Much is Too Much?
Psychiatrists, Psychiatric Nurses, Institute of Living, Hartford, CT.
Jun 24, 2002
July 10, 2002
July 17, 2002
July 22, 2002
QTc Prolongation: How Much is Too Much?
Psychiatrist’s Monthly Meeting, Institute of Living, Hartford, CT.
An Update on New Pharmacologic Agents for Advanced Cardiac Life
Support
Pharmacists. Bristol Hospital, Bristol, CT.
An Update on New Pharmacologic Agents for Advanced Cardiac Life
Support
Emergency Room, Critical Care Personnel. Waterbury Hospital, Waterbury,
CT.
The Pharmacologic Management of Heart Failure.
Pharmacists, Cardiac Nurses. New Britain General Hospital, New Britain,
CT.
July 24, 2002
August 6, 2002
October 7, 2002
October 9, 2002
October 17, 2002
November 10, 2002
November 19, 2002
An Update on New Pharmacologic Agents for Advanced Cardiac Life
Support
Emergency Department Grand Rounds: Emergency Department Physicians. Sinai
Hospital, Baltimore, MD.
Administration of PPIs in patients Who Cannot Swallow.
Pharmacy Department. Baystate Medical Center. Springfield, MA.
Administration of Proton Pump Inhibitors through Nasogastric Tubes.
Teleconference: Eastern Medical Science Liasons. AstraZeneca Pharmaceuticals.
Administration of Proton Pump Inhibitors through Nasogastric Tubes.
Teleconference: Western Seaboard Medical Science Liasons. AstraZeneca
Pharmaceuticals.
New Choices for the Cardiac Patient.
CE Program: American Heart Association. Connecticut Society for Cardiac
Rehabilitation: Nurse Practitioners, Physician Assistants, Allied Health:
Wallingford, CT
Racial Differences in Heart Failure Pharmacotherapy.
CE Program: American College of Clinical Pharmacists. Salt Lake City, Utah.
Statin Induced Muscle Toxicity: Impact of Pharmacology and
Pharmacokinetics.
CE Program: CVS Pharmacy: Community Pharmacists: Danbury, CT
December 9, 2002
Moderator: Critical Differences of Cardiovascular Drugs II
December 9, 2002
CE Program: Midyear Clinical Meeting of the American Society of HealthSystems Pharmacists. Atlanta, GA
Critical Differences Between Beta-Blockers.
CE Program: Midyear Clinical Meeting of the American Society of HealthSystems Pharmacists. Atlanta, GA
December 10, 2002
Moderator: New Drugs with Patient Care Impact
CE Program: Midyear Clinical Meeting of the American Society of HealthSystems Pharmacists. Atlanta, GA
December 10, 2002
January 24, 2002
January 31, 2002
May 15, 2003
July 17, 2003
October 16, 2003
October 25, 2003
Rosuvastatin
CE Program: Midyear Clinical Meeting of the American Society of HealthSystems Pharmacists. Atlanta, GA
Atrial Arrhythmia Update 2002.
Part of the Critical Care and Infectious Disease Pharmacotherapy
Symposium.
CE Program: Hospital Pharmacists: Dearborn, MI.
Statin Induced Muscle Toxicity: Impact of Pharmacology and
Pharmacokinetics.
Medical Grand Rounds: Phelps Memorial Hospital, NY
Drug-Drug Interactions: The Heart of the Matter
Medical Grand Rounds: Middlesex Hospital, Middlesex, CT
To Take or Not To Take: Herbs in Cardiovascular Disease.
Patient Education Seminar: Congestive Heart Failure Clinic Patients and Their
Families.
Hartford Hospital, Wethersfield Campus, Wethersfield, CT
Statin Induced Muscle Toxicity: Impact of Pharmacology and
Pharmacokinetics.
PharmaCE. CE Program: Community Pharmacists: LaGuardia Sheraton, Flushing,
NY
Clash of the Titans: A Comprehensive Review of HMG CoA RIs.
CME Program: Pharmacists, Physicians, Nurse Practitioners: Hartford Hospital
Department of Cardiology: Rocky Hill Marriott, Rocky Hill, CT.
November 11, 2003
November 12, 2003
November 12, 2003
November 18, 2003
November 29, 2003
December 11, 2003
January 20, 2004
February 5, 2004
February 19, 2004
March 11, 2004
March 16, 2004
March 29, 2004
May 13, 2004
June 21, 2004
July 27, 2004
July 27, 2004
August 14, 2004
September 14, 2004
Drug-Drug Interactions: The Heart of the Matter
Medical Grand Rounds: Mercy Medical Center, Springfield, MA
Statin Induced Muscle Toxicity: Impact of Pharmacology and
Pharmacokinetics.
PharmaCE. CE Program: Community Pharmacists: Farmington Marriott,
Farmington, CT
Angiotensin Receptor Blockers: Around the World in 44 Minutes.
PharmaCE. CE Program: Community Pharmacists: Farmington Marriott,
Farmington, CT
The Rhythm is Gonna Get You! Research in Preventing and Treating
Arrhythmias.
Hewitt Pharmacy Research Symposium. University of Connecticut, Storrs, CT
State of the Art in Stable Angina Treatment.
Medical Grand Rounds: Stamford Medical Center: Stamford, CT
Critical Differences of Antiarrhythmic Agents.
CE Program: ASHP Midyear Clinical Meeting: New Orleans, LA.
Drug-Drug Interactions: The Heart of the Matter.
CE Program: CSHP Hospital Pharmacists Monthly Meeting: Rocky Hill, CT.
Advances in the Treatment of Hyperlipidemia.
CE Program: CPA Community Pharmacists: Annual Meeting: Southington, CT
Advancing into a New Era of Anticoagulant Therapy.
CE Program: Anticoagulation Pharmacists/Nurses/Physicians. Edison, NJ
Advancing into a New Era of Anticoagulant Therapy.
CE Program: Pharmacists/Nurses/Physicians. Hartford, CT
Advancing into a New Era of Anticoagulant Therapy.
CE Program: Pharmacists/Nurses/Physicians. Newburgh, NY
HMG CoA RI: Critical Safety Differences.
Physicians: Baystate Medical Center. Springfield, MA.
New Anticoagulants For Cardiac and Vascular Disorders.
CE Program: Third Annual Henry Low Heart Center Nursing Symposium.
Hartford, CT
Oral Anticoagulants: A Review of Current and Future Treatments.
CE Program. ASHP Annual Meeting, Las Vegas, NV.
Statin Induced Muscle Toxicity: Innate Risk and Impact of Drug Interactions.
CE Program, Pharmacists. Hackensack University Medical Center, Hackensack,
NJ
Statin Induced Muscle Toxicity: Innate Risk and Impact of Drug Interactions.
CE Program, Physicians, Nurse Practitioners. Saint Joseph’s Hospital,
Hackensack, NJ
Angiotensin Receptor Blockers: Around the World in 44 Minutes.
CE Program: Philippine-American Physicians/ Northeast Chapter Annual Meeting.
Foxwoods, CT.
Statin Induced Muscle Toxicity: Innate Risk and Impact of Drug Interactions.
CE Program, Physicians, Pharmacists: Federal Healthcare/Dept of Defense
Lecture Series. Washington, DC.
September 17, 2004
September 30, 2004
Women and Cardiac Disease.
CE Program, Pharmacists, Connecticut Pharmacists Association. Rocky Hill, CT
Impact of ARBs on Renal Function in Type 2 Diabetics.
CE Program, Physicians, Nurses: Healthwise Medical Associates, Vernon, CT.
October 1, 2004
October 15, 2004
November 2, 2004
December 7, 2004
December 15, 2004
May 17, 2005
May 18, 2005
May 18, 2005
June 15, 2005
September 16, 2005
December 6, 2005
December 28, 2005
March 21, 2006
November 8, 2006
December 2, 2006
December 27, 2006
March 10, 2007
March 13, 2007
April 18, 2007
September 19, 2007
Oral Anticoagulants: A Review of Current and Future Treatments
CE Program. CSHP Catch the Wave Meeting. Farmington, CT
Statin Induced Muscle Toxicity: Innate Risk and Impact of Drug Interactions.
CE Program, Physicians, Pharmacists: Newark, NJ
Pharmacotherapy of Hypertension.
CE Program, Pharmacists, PharmEd. Rocky Hill, CT
Critical Differences of ARBs.
CE Program. Pharmacists: ASHP Midyear Clinical Meeting. Orlando, FL.
Statin Induced Muscle Toxicity: Innate Risk and Impact of Drug Interactions.
Dinner Program. Physicians. Poughkeepsie, NY.
Hypertension: Epidemiology, Pathophysiology and Pharmacotherapy.
Noontime Conference: Pioneer Valley Cardiologists.
Moderator: Critical Differences Between Cardiac Drugs.
CE Program. Pharmacists. Schwarting Symposium. University of Connecticut.
Storrs, CT.
Antiarrhythmic Drug Therapy.
CE Program. Pharmacists. Schwarting Symposium. University of Connecticut.
Storrs, CT.
HMG CoA RI Therapy for Hyperlipidemia.
Dinner Program, Physicians & Nurse Practitioners, Providence, RI.
Statins: Efficacy and Muscle Safety Comparisons.
CE Program: Pharmacists. Eugene Applebaum College of Pharmacy. Detroit, MI
Non-Pharmacologic Therapies for Atrial Fibrillation & Flutter.
CE Program: Pharmacists: ASHP Midyear Clinical Meeting. Las Vegas, NV.
Advanced Technology for Cardiac Care.
CE Program: Pharmacists: CE Finale, University of Connecticut, Storrs, CT
New Frontiers, The Use of Inhaled Insulin for Diabetes Mellitus.
CE Program: Pharmacists: CSHP Monthly Meeting: Manor Inn, Milldale, CT
Efficacy and Safety Implications of Intensive Lipid Lowering.
Physicians (Attendings, Fellows), Nurse Practitioners. St Vincent Hospital,
Worcester, MA.
Radiofrequency Ablation Therapy: Use of Anticoagulation.
CE Program, Pharmacists. 21st Annual Pharmacy Invitational Conference on
Antithrombotic Therapy, Anaheim, CA.
New Frontiers in Herbal Pharmacotherapy & Research.
CE Program, CE Finale. University of Connecticut, Storrs, CT.
Safety and Efficacy Implications of Statin Therapy.
CE Program, Pharmacy Practice Institute, Albany College of Pharmacy, Albany
Marriott, Albany, NY.
Treatment of Myocardial Infarction: PICCs Format
CE Program. Connecticut Society of Health-System’s Pharmacists, Rocky Hill, CT
Acute Ischemic Stroke
CE Program. Connecticut Pharmacists Association, Trumbull, CT
Keynote Address: Antiarrhythmic Drug Prophylaxis in the Open Heart
Surgery Patient: Cost Effectiveness and Quality Issues.
Twentieth Annual Heartbeats Symposia: The Forum Conference and Education
Center, Cleveland, Ohio. [Note: The only Non-Physician Invited as Speaker]
Research Evaluating my Teaching
Section H
C. Michael White, Pharm.D., FCP, FCCP
Professor of Pharmacy
University of Connecticut
In 2006 I developed a new approach to teach case based information called Pharmacist
Interactive Clinical Cases. This approach was designed to be more interactive, clinically
relevant, and fun to complete. I piloted the cases on experiential rotation students and
gathered data on their perceptions via a survey tool. I used it in Therapeutics 254 in
Spring 2007 and also administered a survey asking for student perceptions. Students in
both surveys rated the PICCs surveys much higher than traditional case based learning
approaches. The manuscript summarizing these findings is given in the following
attachment.
Book Chapters and Review Articles of Note
Section I
C. Michael White, Pharm.D., FCP, FCCP
Professor of Pharmacy
University of Connecticut
Book chapters and review articles are important teaching modalities for pharmacists and
students. By summarizing the current literature and presenting in a way that empowers
and engages the reader, effective distance learning occurs. Of particular note, I have coauthored book chapters in Applied Therapeutics and the Pharmacotherapy SelfAssessment Program which are high visibility and high impact books. Several of my
review articles in the Annals of Pharmacotherapy or US Pharmacist have been given
accompanying CE questions.
NON-RESEARCH
PUBLICATIONS
BOOK
CHAPTERS
(15 Published/In Press. 1 in Progress)
February 2001
Chow MSS, White CM. Cardiac Arrhythmias, Chapter 18. In: Koda-Kimble
MA, Young LY (Eds). Applied Therapeutics: The Clinical Use of Drugs. 7th Edition.
Lippincott Williams & Wilkins, Philadelphia, PA. 2001: pg 18.1-18.36.
April 2002
Chow MSS, White CM. Cardiac Arrhythmias, Chapter 17. In: Koda-Kimble
MA, Young LY (Eds). Handbook of Applied Therapeutics. 7th Edition. Lippincott
Williams & Wilkins Philadelphia, PA 2001: pg 17.1-17.16.
August 2002
White CM. Cardiac Arrhythmias, Chapter 5. In: Jeffrey S (Ed). Geriatric
Pharmacy Certification Program Review Coursebook, 3rd Edition. American Society
of Consultant Pharmacists, Alexandria, VA. Accessed at
GeriatricPharmacyReview.com.
January 2004
White CM, McBride B, Kalus J. Dyslipidemias, Chapter 2. In: Schumock GT,
Brungage DM, et al (Eds). Pharmacotherapy Self Assessment Program, Fifth
Edition, Book 1 Cardiology. American College of Clinical Pharmacy Inc, Kansas
City. MO. 2004: pg 165-190.
August 2004
White CM, Song J, Chow MSS. Cardiac Arrhythmias, Chapter 20. In: KodaKimble MA, Young LY (Eds). Applied Therapeutics: The Clinical Use of Drugs. 8th
Edition. Lippincott Williams & Wilkins, NY, NY. 2004; Pg 20.1-20.33.
April 2005
Caron M, White CM. Fundamental Concepts in Pharmacokinetics and
Pharmacodynamics of Fibrinolytic Agents. In: Becker RC, Harrington RA (Eds).
Clinical, Interventional, and Investigational Thrombocardiology. Marcell Dekker,
Inc, New York, NY. 2005
April 2005
Caron M, Kalus J, McBride B, White CM. Fundamental Concepts in
Pharmacokinetics and Pharmacodynamics of Antithrombotic Agents. In: Becker
RC, Harrington RA (Eds). Clinical, Interventional, and Investigational
Thrombocardiology Marcell Dekker, Inc, New York, NY. 2005
April 2005
White CM, Song J, Chow MSS. Cardiac Arrhythmias, Chapter 20. In: KodaKimble MA, Young LY (Eds). Handbook of Applied Therapeutics. 8th Edition.
Lippincott Williams & Wilkins, NY, NY. 2005; Pg 20.1-20.15.
June 2005
White CM. Cardiac Arrhythmias, Chapter 5. In: Jeffrey S (Ed). Geriatric
Pharmacy Certification Program Review Coursebook, 4th Edition. American Society
of Consultant Pharmacists, Alexandria, VA. Accessed at
GeriatricPharmacyReview.com.
August 2005
White CM, McBride BF, Kalus J. Dyslipidemia Algorithms. In: Kishi W. A
Guide to Clinical Decision-Making: The PSAP Algorithms, Third Edition.
American College of Clinical Pharmacy Inc, Kansas City, MO 2005.
April 2006
White CM. Careers in Pharmacy. In: Castagno JM. (Ed). Lands and Peoples: The
New Book of Popular Science. Scholastic Library Publishing, Danbury, CT. pg 46264.
April 2006
Davis G, White CM. Medications and Drugs. In: Castagno JM. (Ed). Lands and
Peoples: The New Book of Popular Science. Scholastic Library Publishing, Danbury,
CT. 2006: pg 460-7.
April 2006
Rhines K, White CM. Drug Delivery Technology. In: Castagno JM. (Ed). Lands
and Peoples: The New Book of Popular Science. Scholastic Library Publishing,
Danbury, CT. 2006: pg 468-75.
January 2007
White CM, Coleman CI. Drug Induced Cardiac Diseases. In: Schumock GT,
Brungage DM, et al (Eds). Pharmacotherapy Self Assessment Program, Sixth
Edition, Book 1 Cardiology. American College of Clinical Pharmacy Inc, Kansas
City. MO. 2007: 39-56.
In Press
White CM, Song J, Kluger J. Research Considerations in Cardiovascular
Therapeutic Areas. Chapter 11. In: Even RP, Smith LJ (Eds). Drug & Biologic
Development. Springer Verlag, Inc., New York, NY.
In Progress
White CM, Song J, Kalus J. Cardiac Arrhythmias, Chapter __. In: Koda-Kimble
MA, Young LY (Eds). Applied Therapeutics: The Clinical Use of Drugs. 9th Edition.
Lippincott Williams & Wilkins, NY, NY. 2007 pg __ to __.
White CM, Song J, Chow MSS. Cardiac Arrhythmias, Chapter __. In: KodaKimble MA, Young LY (Eds). Handbook of Applied Therapeutics. 9th Edition.
Lippincott Williams & Wilkins, NY, NY. 2008; Pg __- __.
BOOKS
June 2001
(1 Published)
White CM, Dunn A, Reddy P. Angina Pectoris Disease State Management
Module. University of Kentucky College of Pharmacy, Lexington, KY. 2001.
REVIEW ARTICLES
July 1996
(72 Published or In Press)
White CM. Treatment of Hypercholesterolemia
US Pharmacist 1996;21:76-90.
November 1996
White CM, Chow MS. Beyond ACE inhibition: The Role of Angiotensin II Type
1 Receptor Blockers in Cardiovascular Medicine.
Formulary 1996;31:1058-64.
December 1996
White CM. Drug Induced Respiratory Depression.
US Pharmacist 1996;21:970-85.
December 1996
Milch LM, White CM, Wolfe S. Focus of Fluticasone
Formulary 1996;31:1165-77.
February 1997
White CM. Weight Based Heparin Dosing Versus Standard Dosing
Connecticut Medicine 1997;61:103-104.
March 1997
White CM, Chow MS. The Role of Positive Inotropic Agents in Severe Heart
Failure
Formulary 1997;32:255-266.
April 1997
White CM, Chow MS. Future Pharmacotherapeutic Options in the Treatment
of Heart Failure
US Pharmacist 1997;22:117-130.
September 1997
White CM. The Use of Aspirin for the Prevention and Treatment of Coronary
Artery Disease
US Pharmacist 1997;22:116-134.
October 1997
White CM. The Role of Calcium Channel Blockers in Congestive Heart Failure
Connecticut Medicine 1997;61:669-71.
November 1997
White CM, Chow MS. Reassessing the Risks of Calcium Channel Blockers In
Medicine
Formulary 1997;32:1146-65.
January 1998
White CM, Chow MS. A Review of HMG CoA Reductase Inhibitors
US Pharmacist 1998;23:HS19-HS30.
March 1998
White CM, Chow MSS. Applying Principles of Chronotherapy to Drug Delivery
Systems and Dosage Times
Formulary 1998;33:208-220.
April 1998
White CM. Catecholamines and Their Blockade in Heart Failure
American Journal of Health-Systems Pharmacists 1998;55:676-682.
June 1998
White CM. A Review of the Pharmacologic, Pharmacokinetic, and Therapeutic
Differences Between ACE Inhibitors
Pharmacotherapy 1998;18:588-599.
February 1999
White CM. Pharmacological Effects of HMG CoA Reductase Inhibitors Other
Than Lipoprotein Modulation
Journal of Clinical Pharmacology 1999;39:111-8.
May 1999
White CM. Cardiovascular Effects, Pharmacokinetics, and Side Effects of
Intravenous Glucagon Administration.
Journal of Clinical Pharmacology 1999;39:442-7.
June 1999
White CM, Dicks RS. Focus on Rivastigmine: An Acetylcholinesterase Inhibitor
for Patients with Alzheimer’s Disease.
Formulary 1999;34:493-9.
October 1999
White CM. Prevention of Sub-Optimal Beta-Blocker Treatment in Patients with
Myocardial Infarctions.
Annals of Pharmacotherapy 1999;33:1063-72.
December 1999
Song J, White CM.* Beta-Adrenoceptor Blockers in Heart Failure.
Connecticut Medicine 1999;63:719-22.
* = Corresponding Author
January 2000
Tsikouris JP, White CM,* Kluger J. Optimizing Oral Dosing and Monitoring of
Noncardiac Toxicities with Chronic Amiodarone Therapy.
Connecticut Medicine 2000;64:35-8.
* = Corresponding Author
February 2000
Song J, White CM.* Pharmacologic, Pharmacokinetic, and Therapeutic
Differences Among Angiotensin II Receptor Antagonists.
Pharmacotherapy 2000;20:130-9.
* = Corresponding Author
February 2000
White CM, Tsikouris J. A Review of the Pathophysiology and
Pharmacotherapy of Vasovagal Syncope.
Pharmacotherapy 2000;20:158-65.
April 2000
White CM. An Evaluation of CYP 3A4 Drug Interactions with HMG CoA
Reductase Inhibitors.
Formulary 2000;35:343-52.
August 2000
Tsikouris J, White CM.* Focus on Tenectaplase.
Formulary 2000;35:647-53.
* = Corresponding Author
September 2000
White CM. A Pharmacokinetic Comparison of HMG CoA Reductase
Inhibitors.
Connecticut Medicine 2000;64:533-5.
October 2000
White CM. ACE Inhibition in Patients Following Myocardial Infarction or
With Heart Failure.
American Journal of Health-System Pharmacists 2000;57(Suppl):s18-s25.
October 2000
Song J, White CM.* Tykosyn ® (Dofetilide).
Connecticut Medicine 2000;64:601-4.
* = Corresponding Author
February 2001
Song JC, White CM.* Do HMG CoA Reductase Inhibitors Affect
Fibrinogen?
Annals of Pharmacotherapy 2001;35:236-41.
* = Corresponding Author
March 2001
Caron M, White CM.* Intravenous Amiodarone For Cardiac Arrest.
Connecticut Medicine 2001;65:81-2.
* = Corresponding Author
April 2001
Caron M, White CM.* An Evaluation of the Antihypercholesterolemic Effects
of Herbal Products
Pharmacotherapy 2001;21:481-7.
* = Corresponding Author
June 2001
Markelon J, Caron M, Song J, White CM.* Tips for Safely Withdrawing Other
Antiarrhythmics Before Initiating Dofetilide.
Formulary 2001;36:471.
* = Corresponding Author
July 2001
Song J, White CM.* Focus on Olmesartan Medoxomil (Cs-866): An Angiotensin
Receptor Blocker for Treatment of Hypertension.
Formulary 2001;36:487-99.
* = Corresponding Author
September 2001
Caron M, White CM.* Focus on Nesiritide – An Update.
Formulary 2001;36:639-43.
* = Corresponding Author
October 2001
Caron M, Kluger J, White CM.* Amiodarone in the New AHA Guidelines for
Ventricular Tachyarrhythmias.
Annals of Pharmacotherapy 2001;35:1248-54.
* = Corresponding Author
October 2001
Song J, White CM.* Focus on Omapatrilat.
Formulary 2001;36:698-707.
* = Corresponding Author
October 2001
Kalus J, White CM.* A Comprehensive Review of Antihypertensive Agents
Providing Renal Protection.
Connecticut Medicine 2001;65:587-91.
* = Corresponding Author
November 2001
Caron M, Kuti J, Quintilliani R, White CM.* Focus on Drotrecogin Alpha
(Activated): A New Approach to Treating Sepsis.
Formulary 2001;36:784-95.
* = Corresponding Author
April 2002
Song J, White CM.* Clinical Pharmacokinetics and Selective
Pharmacodynamics of Newer ACE Inhibitors: An Update.
Clinical Pharmacokinetics 2002;41:207-24.
* = Corresponding Author
May 2002
Kalus J, White CM.* Focus on Lercanidipine: a Long-Acting Dihydropyridine
Calcium Channel Blocker.
Formulary 2002;37:234-8.
* = Corresponding Author
August 2002
White CM. Do Atypical Antipsychotics Increase the QTc Interval?
Connecticut Medicine 2002;66:461-3.
September 2002
White CM. Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin.
Journal of Clinical Pharmacology 2002;42:963-70.
September 2002
Coleman C, Reddy P, White CM. Budesonide: It’s Role in Chrohn’s Disease
Therapy.
Connecticut Medicine 2002;66:523-6.
October 2002
Coleman C, Reddy P, Song J, White CM.* Focus on Eplerenone: The First
Selective Aldosterone Receptor Antagonist for the Treatment of Hypertension.
Formulary 2002;37:514-24.
* = Corresponding Author
November 2002
Kalus J, White CM.* A Comparison of Amlodipine to Angiotensin II Type-1
Receptor Blockers for Non-Hypertension Indications.
Annals of Pharmacotherapy, 2002;36:1759-66.
* = Corresponding Author
November 2002
White CM. HMG CoA Reductase Inhibitor Induced Muscle Toxicity: Risks,
Monitoring, and Management.
Formulary 2002;37:583-93.
December 2002
Kalus J, White CM.* Monitoring Anti-factor Xa Activity of the Low-MolecularWeight Heparins in the Clinical Setting: Who, Why, How, and When?
Connecticut Medicine 2002;66:749-51.
* = Corresponding Author
May 2003
White CM. Venlafaxine in EP Procedure?
Clinical Case Review Featured in Clinical Twisters Segment.
Drug Topics 2003;147:HSE11.
August 2003
McBride B, White CM.* Acute Decompensated Heart Failure: A
Comtemporary Approach to Pharmacotherapeutic Management.
Pharmacotherapy 2003;997-1020.
* = Corresponding Author
August 2003
McBride BF, White CM.* Ranolazine: A Novel Metabolic Modulator for the
Treatment of Chronic Stable Angina.
Formulary 2003;38:461-6.
* = Corresponding Author
August 2003
Perkerson K, Coleman CI, White CM. Aldosterone Receptor Antagonists in the
Treatment of Heart Failure.
Connecticut Medicine 2003;67:397-400.
September 2003
McBride B, White CM.* Levosimendan: Implications for Clinicians.
Journal of Clinical Pharmacology 2003;43:1071-81.
* = Corresponding Author
November 2003
McBride B, White CM.* Are There Ethnic Differences in Heart Failure
Medication Response?
Connecticut Medicine 2003;67:605-8.
* = Denotes Corresponding Author
February 2004
Cheng JW, Frank L, Garrett SD, Lu Y, Sanoski CA, White CM. Key Articles
and Guidelines in Pharmaceutical Management of Arrhythmia.
Pharmacotherapy 2004;24:248-279
March 2004
Min B, White CM.* Hawthorn.
Connecticut Medicine 2004;68:161-4.
* = Denotes Corresponding Author
June 2004
Kluger J, White CM. Amiodarone Prevents Symptomatic Atrial Fibrillation
and Reduces the Risk of Cerebrovascular Accidents and Ventricular
Tachycardia after Open Heart Surgery: Results of the Atrial Fibrillation
Suppression Trial (AFIST).
Cardiac Electrophysiology Review 2003;7:165-7.
June 2004
McBride B, White CM.* Anemia Management in Heart Failure: A Thick
Review of Thin Data.
Pharmacotherapy 2004;24:757-67.
* = Corresponding Author
August 2004
Gillespie E, Perkerson K, White CM, Coleman CI. Possible Impact of Aprotinin
on Post-Cardiothoracic Surgery Atrial Fibrillation.
Connecticut Medicine 2004;68:439-42.
August 2004
Sander S, White CM.* Focus on Ximelagatran: A New Oral Anticoagulant.
Formulary 2004;39:398-404.
* = Denotes Corresponding Author
September 2004
Coleman CI, Linberg M, Perkerson K, White CM.* Focus on:
Simvastatin/Ezetimibe.
Formulary 2004;39:437-44.
* = Denotes Corresponding Author
October 2004
Coyle J, Gardner S, White CM.* Angiotensin Receptor Blockers in
Hypertensive Patients With Type II Diabetes Mellitus.
Annals of Pharmacotherapy 2004;38:1731-8.
* = Denotes Corresponding Author
Featured Article with CE Questions and Credits.
November 2004
Henyon N, White CM.* Adjunctive Intravenous Magnesium to Reduce Toxicity
and Enhance Efficacy of Class III Antiarrhythmic Agents.
Connecticut Medicine 2004;68:627-9.
* = Denotes Corresponding Author
December 2004
White CM. Thrombin Directed Inhibitors: Pharmacology and Clinical Use.
American Heart Journal 2004;149:s54-s60.
January 2005
McBride BF, White CM.* Critical Differences Among Beta-Adrenoceptor
Antagonists in Heart Failure: Debating the MERIT of COMET.
J Clin Pharmacol 2005;45:6-24.
* = Denotes Corresponding Author
February 2005
Sander S, White CM.* The Use of Prophylactic Amiodarone After
Cardiothoracic Surgery Reduces the Incidence of Atrial Fibrillation
Connecticut Medicine 2005;69:91-4.
* = Denotes Corresponding Author
June 2005
Henyon N, White CM.* Focus on Ranolazine: An Update.
Formulary 2005;40:323-328.
* = Denotes Corresponding Author
December 2005
Patel AA, White CM, Coleman CI. Focus on Exubra, an Inhaled Insulin.
Formulary 2005;40:429-36.
June 2006
ASHP Commission on Therapeutics. ASHP Therapeutic Position Statement on
the Treatment of Hypertension.
Am J Health Sys Pharm 2006;63:1074-80.
August 2006
Dale K, White CM.* The Use of Intravenous Amiodarone for Chemical
Conversion of Atrial Fibrillation.
Connecticut Medicine 2006; 70:433-8.
* = Denotes Corresponding Author
November 2006
Shah S, White CM.* Focus on Rimonabant: A Novel CB1 Receptor Antagonist
for the Treatment of Obesity.
Formulary 2006;41:561-9.
* = Denotes Corresponding Author
February 2007
Patel AA, White CM, Coleman CI. Protamine to Rapidly Reduce Anticoagulant
Effect of Heparin in Percutaneous Coronary Intervention.
Connecticut Medicine 2007;71:93-5.
March 2007
Baker W, White CM.* Post-Cardiothoracic Atrial Fibrillation: A Review of
Preventive Strategies.
Ann Pharmacother 2007;41: DOI 10.1345/aph.1H594
* = Denotes Corresponding Author
April 2007
Baker WL, White CM.* Renin-Angiotensin System Inhibitors for Prevention of
New Onset Atrial Fibrillation.
Connecticut Medicine 2007;71:205-9.
* = Denotes Corresponding Author
April 2007
Dale K, White CM.* Dronedarone: An Amiodarone Analog for the Treatment
of Atrial Fibrillation and Atrial Flutter.
Ann Pharmacother 2007;41:DOI 10.1345/aph.1H524.
* = Denotes Corresponding Author
May 2007
Reinhart K, White CM.* Focus on Sitaxsentan.
Formulary 2007;42:295-301.
* = Denotes Corresponding Author
Shah, S, Kluger, J, White CM.* Dual Antiarrhythmic Therapy.
Pharmacotherapy, In Press.
* = Denotes Corresponding Author
Sanoski C, Cheng JW, Kalus JS, White CM. Key Articles and Guidelines in
Pharmaceutical Management of Arrhythmia.
Pharmacotherapy, In Press
Editorials
January 2006
December 2006
(n=2)
White CM. Should all Patients Receive Prophylactic Amiodarone Therapy
Before Cardiac Surgery?
Nature, Clinical Practice: Cardiovascular Medicine. 2006;3:18-9.
White CM. Assuring Patients Receive Medications Proven to Help Them Live
Longer: A Pharmacists Call to Arms.
Annals of Pharmacotherapy 2006;40:2248-50.
Summary of Review Article/Editorial Publications (n=74)
22= Formulary (Impact Factor 0.220)
20 = Connecticut Medicine (Impact Factor Unknown)
8 = Annals of Pharmacotherapy (Impact Factor 1.822)
7 = Pharmacotherapy (Impact Factor 2.002)
5 = Journal of Clinical Pharmacology (Impact Factor 1.945)
5 = US Pharmacist (Impact Factor Unknown)
3 = American Journal of Health-System Pharmacists (Impact Factor 1.44)
1 = Clinical Pharmacokinetics (Impact Factor 3.899)
1 = American Heart Journal (Impact Factor 3.300)
1 = Nature, Clinical Practice: Cardiovascular Medicine (Impact Factor Unknown)
1 = Cardiac Electrophysiology Review (Impact Factor Unknown)
1 = Drug Topics (Impact Factor Unknown)
Teaching Portfolio
C. Michael White, Pharm.D., FCP, FCCP
Professor
Department of Pharmacy Practice
University of Connecticut